The assessment of potential for QT interval prolongation with new pharmaceuticals: Impact on drug development

Journal of Pharmacological and Toxicological Methods

Volumn 43, Issue 2, 2000, Pages 91-99

  Gralinski, Michael R ^a  

^a PFIZER INC   (United States)

Author keywords

Drug development; Electrocardiogram; QT interval

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ASTEMIZOLE; CISAPRIDE; DIPHENHYDRAMINE; ERYTHROMYCIN; FEXOFENADINE; FLUCONAZOLE; GREPAFLOXACIN; HALOPERIDOL; HISTAMINE H1 RECEPTOR ANTAGONIST; KETOCONAZOLE; MACROLIDE; NEUROLEPTIC AGENT; PHENOTHIAZINE DERIVATIVE; PROTEIN SYNTHESIS INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RISPERIDONE; SERTINDOLE; TERFENADINE;

ARTICLE; AWARENESS; CLINICAL EXAMINATION; CLINICAL PRACTICE; ELECTROCARDIOGRAM; HEART REPOLARIZATION; HUMAN; LONG QT SYNDROME; MUSCLE ACTION POTENTIAL; POLICY; PRACTICE GUIDELINE;

ACTION POTENTIALS; ANIMALS; ARRHYTHMIA; ELECTROCARDIOGRAPHY; HEART; HUMANS; LONG QT SYNDROME;

EID: 0034524910     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8719(00)00100-3     Document Type: Article

References (60)

1. The long QT syndrome: Ion channel diseases of the heart
2. Systemic antifungal agents. Drug interactions of clinical significance
3. Effects of quinidine on repolarization in canine epicardium, midmyocardium, and endocardium: II. In vivo study
4. Histamine, bradykinin, and their antagonists
5. An analysis of the time-relations of electrocardiograms
6. Ca channels in cardiac myocytes: Structure and function in Ca influx and intracellular Ca release
7. The risk of life-threatening cardiovascular events with terfenadine
8. Antiarrhythmic effects of potassium channel openers in rhythm abnormalities related to delayed repolarization
9. QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: Etiology and interventions
10. Analysis of the ionic basis for cocaine's biphasic effect on action potential duration in guinea-pig ventricular myocytes
11. Blockade of multiple human cardiac potassium currents by the antihistamine terfenadine: Possible mechanism for terfenadine-associated cardiotoxicity
12. Appropriateness of various laboratory species as models
13. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval
14. Die systolendauer im elektrokardiogramm bei normalen menschen und bei herzkranken
15. Acquired QT prolongation: Mechanisms and implications
16. Erythromycin monotherapy associated with torsade de pointes
17. Time course and voltage dependence of expressed HERG current compared with native "rapid" delayed rectifier K current during the cardiac ventricular action potential
18. Molecular mechanisms of arrhythmias
19. A review of erythromycin-induced malignant tachyarrhythmia - Torsade de pointes. A case report
20. Block of potassium currents in guinea pig ventricular myocytes and lengthening of cardiac repolarization in man by the histamine H1 receptor antagonist diphenhydramine
21. Effects of cisapride on QT interval in children
22. Torsade de pointes induced by terfenadine in a patient with long QT syndrome
23. Terfenadine overdose induced polymorphous ventricular tachycardia
24. Physiologic relation between cardiac cycle and QT duration in healthy volunteers
25. Anticholinergic overdose induced torsade de pointes successfully treated with verapamil
26. Torsade de pointe resulting from the addition of droperidol to an existing cytochrome P450 drug interaction
27. Torsade de pointes. Mechanisms and management
28. QT interval prolongation and torsades de pointes due to erythromycin lactobionate
29. Haloperidol-induced torsade de pointes
30. Torsade de pointes induced by quinidine: A case treated successfully with verapamil
31. Torsades de pointes induced by erythromycin and terfenadine
32. Ventricular fibrillation resulting from ischemia at a site remote from previous myocardial infarction. A conscious canine model of sudden coronary death
33. Torsade de pointes induced by cisapride/clarithromycin interaction
34. Risk of developing life-threatening ventricular arrhythmia associated with terfenadine in comparison with over-the-counter antihistamines, ibuprofen and clemastine
35. Torsade de pointes
36. Recent advances in understanding the molecular mechanisms of the long QT syndrome
37. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine
38. Torsade de pointes induced by astemizole in a patient with prolongation of the QT interval
39. Kr potassium channel
40. + channels
41. The LQT syndromes - Current status of molecular mechanisms
42. Structure and function of cardiac potassium channels
43. The heart rate corrected QT interval of conscious beagle dogs: A formula based on analysis of covariance
44. Insights into the structure, distribution and function of the cardiac chloride channels
45. An improved method to correct the QT interval of the electrocardiogram
46. Long QT syndromes and torsade de pointes
47. Cisapride-induced torsades de pointes
48. Enhanced susceptibility for acquired torsade de pointes arrhythmias in the dog with chronic, complete AV block is related to cardiac hypertrophy and electrical remodeling
49. Reproducible induction of early afterdepolarizations and torsade de pointes arrhythmias by d-sotalol and pacing in dogs with chronic atrioventricular block
50. The structure and function of the cardiac myocyte: A review of fundamental concepts
51. Genetics, molecular mechanisms and management of long QT syndrome
52. Experimental models of torsades de pointes
53. Case report of phenothiazine-induced torsade de pointes
54. Mechanism of the cardiotoxic actions of terfenadine
55. Electrocardiographic findings in patients with diphenhydramine overdose
56. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels